Clinical trials
Systemic Inflammatory Response clinical trials
Below are recruiting systemic inflammatory response clinical trials, each written for real people, not researchers. We’re tracking 60 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06916806RecruitingPhase 1
Study of AZD5492 for lupus, myositis, or rheumatoid arthritis
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
Anniston, AlabamaAges 18–70 - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06118034RecruitingPhase 3
Colchicine for heart surgery recovery
This study tests whether the drug colchicine can reduce inflammation and protect organs during and after planned heart surgery. It may help people recover better.
Nanjing, JiangsuAges 50–80 - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT06092463Recruiting
Immune system study in newborn intestines
This study looks at how the immune system develops in the intestines of newborns, including those born early or with a blocked intestine (atresia). It may help doctors understand inflammation and improve care for sick babies.
CopenhagenAges Up to 1 year - NCT07527247RecruitingPhase 2
Testing a New Yellow Fever and Dengue Vaccine
This study tests a new vaccine designed to improve protection against yellow fever and dengue fever in healthy adults. Researchers want to see if this vaccine works better than existing ones and is safe.
SingaporeAges 21–59 - NCT06573034Recruiting
Standing meditation study for young adults with stress
This study tests if a gentle standing meditation practice (called Daoist Zhanzhuang) can help young adults feel better and handle stress. You would practice for 30 minutes at a time and be followed for a year.
Charlotte, North CarolinaAges 18–25 - NCT06440694RecruitingPhase 3
Colchicine to reduce inflammation after a first blood clot in the leg
This trial tests if colchicine, a medicine used for gout, can reduce inflammation after a first deep vein thrombosis (blood clot in a large leg vein). It might help prevent long-term leg problems from the clot.
Ottawa, OntarioAges 18 years+ - NCT04843982RecruitingPhase 4
Esketamine to reduce inflammation in septic adults
This trial studies whether esketamine can improve the body’s overactive inflammation during sepsis. Participants are adult ICU patients who are sick enough to need breathing support and have higher severity scores.
Wuhan, HubeiAges 18–80 - NCT05459207Recruiting
Body fat and pain after spinal cord injury
This study looks at how body composition (amount and distribution of body fat) relates to pain in people with spinal cord injury. It may help researchers understand why pain differs from person to person after spinal cord injury.
Coral Gables, FloridaAges 18–70 - NCT05670301Recruiting
Blood test study to profile inflammation biomarkers in diseases
This study measures blood “biomarkers” (signals in blood) to better understand inflammatory diseases, including autoimmune and autoinflammatory conditions. You may be asked to give blood samples now and possibly extra samples if needed for testing.
AntwerpAges Any age - NCT05968742Recruiting
Study of how gums respond to irritation
This study looks at how your gums react when exposed to a controlled irritant, comparing different gum response patterns. It may help researchers understand why gum inflammation happens and how to prevent it.
Seattle, WashingtonAges 18–35 - NCT06479018Recruiting
Understanding IL-17's role in Bullous Pemphigoid inflammation
This study looks at how a specific immune system protein (IL-17) affects inflammation in a blistering skin disease called Bullous Pemphigoid. It aims to better understand the disease to help develop future treatments.
ReimsAges 18 years+ - NCT07459049RecruitingPhase 4
Ibuprofen for gum inflammation after deep cleaning
This trial tests whether ibuprofen can help calm gum inflammation after a deep cleaning for periodontitis. It is for adults with moderate-to-severe gum disease who are otherwise healthy.
BaghdadAges 18 years+ - NCT07636733Recruiting
Vitamin D for Gum and Bone Health in Periodontal Disease
This study tests whether vitamin D supplements can reduce inflammation and improve healing in people with gum disease, ranging from mild gingivitis to advanced periodontitis. Researchers will compare how vitamin D affects different stages of gum disease.
RizeAges 18–70 - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75
Hear when a new Systemic Inflammatory Response trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic inflammatory response?
- Yes. Clin2 currently lists 60 recruiting systemic inflammatory response studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic inflammatory response trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic inflammatory response trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.